Targeted Antioxidative and Neuroprotective Properties of the Dopamine Agonist Pramipexole and Its Nondopaminergic Enantiomer SND919CL2x [(+)2-Amino-4,5,6,7-tetrahydro-6-lpropylamino-benzathiazole Dihydrochloride]
- 1 January 2006
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 316 (1) , 189-199
- https://doi.org/10.1124/jpet.105.092312
Abstract
Pramipexole has been shown to possess neuroprotective properties in vitro that are partly independent of its dopaminergic agonism. The site of neuroprotective action is still unknown. Using [3H]pramipexole, we show that the drug enters and accumulates in cells and mitochondria. Detoxification of reactive oxygen species (ROS) by pramipexole is shown in vitro and in vivo by evaluating mitochondrial ROS release and aconitase-2 activity, respectively. Pramipexole and its (+)-enantiomer SND919CL2X [low-affinity dopamine agonist; (+)2-amino-4,5,6,7-tetrahydro-6-l-propylamino-benzathiazole dihydrochloride] possess equipotent efficacy toward hydrogen peroxide and nitric oxide generated in vitro and inhibit cell death in glutathione-depleted neuroblastoma cells. IC50 values ranged from 15 to 1000 μM, consistent with the reactivity of the respective radical and the compartmentalization of ROS generation and ROS detoxification. Finally, both compounds were tested in superoxide dismutase 1-G93A mice, a model of familial amyotrophic lateral sclerosis. SND919CL2X (100 mg/kg) prolongs survival time and preserves motor function in contrast to pramipexole (3 mg/kg), which shows an increase in running wheel activity before disease onset, presumably caused by the dopaminergic agonism. We conclude that both enantiomers, in addition to their dopaminergic activity, are able to confer neuroprotective effects by their ability to accumulate in brain, cells, and mitochondria where they detoxify ROS. However, a clinical use of pramipexole as a mitochondria-targeted antioxidant is unlikely, because the high doses needed for antioxidative action in vitro are not accessible in vivo due to dopaminergic side effects. In contrast, SND919CL2X may represent the prototype of a mitochondria-targeted neuroprotectant because it has the same antioxidative properties without causing adverse effects.This publication has 42 references indexed in Scilit:
- Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotectionNeuroscience Letters, 2005
- Involvement of dopamine D2/D3 receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cellsExperimental Neurology, 2004
- Pramipexole protects against apoptotic cell death by non‐dopaminergic mechanismsJournal of Neurochemistry, 2004
- Lessons from models of SOD1-linked familial ALSTrends in Molecular Medicine, 2004
- Oxidative stress in neurodegeneration: cause or consequence?Nature Medicine, 2004
- Effects of high‐intensity endurance exercise training in the G93A mouse model of amyotrophic lateral sclerosisMuscle & Nerve, 2004
- Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatmentAmyotrophic Lateral Sclerosis, 2003
- Midbrain dopaminergic neuronal degeneration in a transgenic mouse model of familial amyotrophic lateral sclerosisAnnals of Neurology, 1997
- Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptorsEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stressNeuron, 1989